Target, Home Depot,...
Health Care: Drugs
Rigel Pharmaceuticals Inc. (RIGL: NASDAQ)
$4.74 -0.11 | -2.27%
05/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 33.48M | 18.63M | 8.88M | 14.72M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 302.46M | 250.23M | 179.93M | 135.97M |
| Property, Plant & Equipment, Gross | 26.06M | 23.10M | 21.00M | 18.33M |
| Accumulated Depreciation & Depletion | 20.24M | 18.22M | 16.47M | 16.04M |
| Property, Plant & Equipment, Net | 5.83M | 4.88M | 4.53M | 2.29M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.76M | 1.99M | 2.24M | 2.48M |
| Total Non-Current Assets | 7.58M | 6.87M | 6.77M | 4.78M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 310.04M | 257.11M | 186.70M | 140.74M |
| Accounts Payable | 1.70M | 1.56M | 1.40M | 3.15M |
| Short Term Debt | 0.00 | 0.00 | 755.00K | 1.06M |
| Other Current Liabilities | 2.12M | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 12.20M | 11.53M | 11.33M | 17.77M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 8.65M | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 96.00K | 9.43M | 9.19M | 12.22M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 8.74M | 9.43M | 9.24M | 13.10M |
| Total Liabilities | 20.95M | 20.96M | 20.56M | 30.88M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 289.10M | 236.15M | 166.13M | 109.87M |
| Common Par | 87.00K | 71.00K | 52.00K | 52.00K |
| Additional Paid In Capital | 1.05B | 897.48M | 741.55M | 723.15M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -760.25M | -661.41M | -575.43M | -613.32M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 82.00K | 6.00K | -38.00K | -12.00K |
| Total Capitalization | 289.10M | 236.15M | 166.13M | 109.87M |
| Total Equity | 289.10M | 236.15M | 166.13M | 109.87M |
| Total Liabilities & Stock Equity | 310.04M | 257.11M | 186.70M | 140.74M |
| Total Common Shares Outstanding | 87.14M | 71.38M | 52.27M | 51.96M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 74.97M | 63.33M | 52.06M | 40.88M |
| Diluted Weighted Shares Outstanding | 74.97M | 63.33M | 52.57M | 40.88M |
| Number of Employees | 157 | 153 | 145 | 142 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with RIGL
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest RIGL Headlines from TheStreet
- 5 Health Care Stocks Under $10 Ready to Rip Higher 04.18.13 | 09:04 pm
- 5 Stocks Poised for Breakouts 04.12.13 | 01:04 pm
- Frail Jobs Gains Gives Markets Jitters 04.05.13 | 04:04 pm
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- 3 Stocks Under $10 Making Big Moves 03.15.13 | 07:03 am
- Stocks Under $10: Blossoming Biotech Play
09.25.12 | 06:09 am - The Next Big Thing in Biotech: Pfizer 05.04.12 | 06:05 am
- Biotech Calendar: Key Dates for October 10.03.11 | 08:10 am
- Vertex Arthritis Pill Shines in Mid-Stage Study 09.06.11 | 08:09 am
- Rigel Stock Falls On Unusually High Volume (RIGL) 05.26.11 | 10:05 am
Press Releases for RIGL
- Rigel Announces Participation At Two Investor Conferences - PR Newswire 02.28.13 | 07:02 am
- Rigel To Present At BIO CEO & Investor Conference - PR Newswire 02.07.13 | 07:02 am
- Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation - PR Newswire 01.03.13 | 07:01 am
- AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis - PR Newswire 12.13.12 | 07:12 am
- Rigel To Present At Jefferies 2012 Global Healthcare Conference In London - PR Newswire 11.08.12 | 07:11 am
- Rigel Announces Pricing Of Public Offering Of Common Stock - PR Newswire 10.03.12 | 09:10 am
- Rigel Announces Proposed Public Offering Of Common Stock - PR Newswire 10.02.12 | 04:10 pm
- Rigel To Present At UBS Global Life Sciences Conference - PR Newswire 09.17.12 | 07:09 am
- Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus - PR Newswire 09.05.12 | 07:09 am
- AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma - PR Newswire 06.19.12 | 08:06 am
Partner Headlines for RIGL
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 12.14.12 | 08:12 am
- Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now - Wall St. Cheat Sheet 07.02.12 | 03:07 am
- Rigel Refuels R&D in $130M Offering - Seeking Alpha 05.29.11 | 08:05 am
- CORRECTED - CORRECTED-BRIEF-Rigel earns $25 million from Astrazeneca - Reuters 09.29.10 | 07:09 am
- AstraZeneca signs arthritis drug deal - Financial Times 02.16.10 | 06:02 pm
- Rigel sees partner for psoriasis drug in 3 months - COO - Reuters 02.16.10 | 03:02 pm
